IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody… Par MarcGuevreguian|2021-03-23T10:16:25+01:00juin 25th, 2019| Lire la suite
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Par MarcGuevreguian|2021-03-23T11:10:41+01:00juin 4th, 2019| Lire la suite
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Par MarcGuevreguian|2021-03-23T11:23:36+01:00mai 30th, 2019| Lire la suite
Emerging translational science discoveries, clonal approaches, and treatment trends… Par MarcGuevreguian|2021-03-23T09:58:52+01:00avril 23rd, 2019| Lire la suite
A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases Par MarcGuevreguian|2021-03-23T10:06:56+01:00avril 19th, 2019| Lire la suite
Thromboembolic events in polycythemia vera Par MarcGuevreguian|2021-03-23T10:04:54+01:00mars 8th, 2019| Lire la suite
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab… Par MarcGuevreguian|2021-03-23T11:15:07+01:00février 27th, 2019| Lire la suite
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients Par MarcGuevreguian|2021-03-23T10:02:16+01:00février 27th, 2019| Lire la suite
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis Par MarcGuevreguian|2021-03-23T10:12:11+01:00février 21st, 2019| Lire la suite
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma Par MarcGuevreguian|2021-03-23T11:17:11+01:00février 5th, 2019| Lire la suite
